GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AVEO Pharmaceuticals Inc (STU:VPA1) » Definitions » Cyclically Adjusted Price-to-FCF

AVEO Pharmaceuticals (STU:VPA1) Cyclically Adjusted Price-to-FCF : (As of Jun. 06, 2024)


View and export this data going back to 2013. Start your Free Trial

What is AVEO Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


AVEO Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for AVEO Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVEO Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

AVEO Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

AVEO Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of AVEO Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, AVEO Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AVEO Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AVEO Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where AVEO Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



AVEO Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

AVEO Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2022 is calculated as:

For example, AVEO Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2022 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2022 (Change)*Current CPI (Sep. 2022)
=0.006/125.2265*125.2265
=0.006

Current CPI (Sep. 2022) = 125.2265.

AVEO Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201212 -5.105 96.871 -6.599
201303 -3.497 98.209 -4.459
201306 -4.887 98.518 -6.212
201309 -3.389 98.790 -4.296
201312 -1.318 98.326 -1.679
201403 -3.861 99.695 -4.850
201406 -2.776 100.560 -3.457
201409 -1.356 100.428 -1.691
201412 -1.663 99.070 -2.102
201503 -2.777 99.621 -3.491
201506 -1.846 100.684 -2.296
201509 1.408 100.392 1.756
201512 0.002 99.792 0.003
201603 -1.593 100.470 -1.986
201606 -0.610 101.688 -0.751
201609 -1.022 101.861 -1.256
201612 -0.930 101.863 -1.143
201703 -0.663 102.862 -0.807
201706 -0.567 103.349 -0.687
201709 -0.211 104.136 -0.254
201712 -0.267 104.011 -0.321
201803 -0.445 105.290 -0.529
201806 -0.604 106.317 -0.711
201809 -0.200 106.507 -0.235
201812 -0.353 105.998 -0.417
201903 -0.563 107.251 -0.657
201906 -0.335 108.070 -0.388
201909 1.068 108.329 1.235
201912 -0.412 108.420 -0.476
202003 -0.663 108.902 -0.762
202006 -0.385 108.767 -0.443
202009 -0.198 109.815 -0.226
202012 -0.407 109.897 -0.464
202103 -0.561 111.754 -0.629
202106 -0.451 114.631 -0.493
202109 -0.200 115.734 -0.216
202112 -0.313 117.630 -0.333
202203 -0.216 121.301 -0.223
202206 -0.067 125.017 -0.067
202209 0.006 125.227 0.006

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AVEO Pharmaceuticals  (STU:VPA1) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


AVEO Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of AVEO Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


AVEO Pharmaceuticals (STU:VPA1) Business Description

Traded in Other Exchanges
N/A
Address
30 Winter Street, Boston, MA, USA, 02108
AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.

AVEO Pharmaceuticals (STU:VPA1) Headlines

No Headlines